Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Great News for Manufacturing and Storage
View:
Post by enriquesuave on Sep 29, 2023 7:39am

Great News for Manufacturing and Storage

FDA will like this aspect of long term drug stability.  It can be packaged and sterilized and kept for up to 8 years.  This means easy manufacturing and FDA compliance.  NDA vs BLA has significant advantages.
Comment by enriquesuave on Sep 29, 2023 7:49am
Dr Lbiati Kaouthar independent director was granted 300 000 options yesterday ($75000 worth). Maybe she is on to something?  
Comment by 99942Apophis on Sep 29, 2023 10:12am
enriquesuave, well stated.  That lady has a history of success and to underline that, means our success!  I still think $3 to $5 this year end.
Comment by Infinity on Sep 29, 2023 10:34am
This is very encoraging.  TLT is rewarding a Fairly new Director.  We have had multiple CEO'S and Dr. Vera who were not granted any stock.  Obviously, she is focused and in-sync with getting the BTD.  Hopefully, she gets the Job done...
Comment by Oilminerdeluxe on Sep 29, 2023 10:55am
Good. Sadly, nothing moves us up anymore. Nevertheless, this was a nice release. 
Comment by Longholder99 on Sep 29, 2023 11:12am
Dr Lbiati must've done something to prompt this reward.  Wonder what milestone she hit?
Comment by Johnandrose22 on Sep 29, 2023 11:30am
"This extended shelf life allows our future commercial partners...." Mr. White's wording in the NR caught my attention. He doesn't say "potential" or "possible" future partners. Perhaps, Dr. Libati's recent compensation is tied to this more declarative statement by the CEO. John
Comment by enriquesuave on Sep 29, 2023 12:39pm
I think that her job is mainly to attract a Big Pharma for partnership rather than for BTD.  I could be wrong.
Comment by DJDawg on Sep 29, 2023 12:44pm
She is Boston based. Boston is a major biotech hub (both biotech offices and venture funding offices) so my hope was always that she could facilitate connections that RDW cannot.
Comment by enriquesuave on Sep 29, 2023 1:00pm
Storage and manufacturing of Adstiladrin definitely do not compare.  ADSTILADRIN is provided as a sterile frozen suspension. Thaw four (4) vials of ADSTILADRIN at room temperature (20°C to 25°C [68°F to 77°F]) until ADSTILADRIN is liquid. Do not expose the vials to higher temperatures. Protect from light. ADSTILADRIN must be brought to room temperature (20°C to ...more  
Comment by enriquesuave on Sep 29, 2023 1:05pm
Or Keytruda  "How long is KEYTRUDA stable for? "); display: inline-block; height: 24px; width: 24px; transform: rotateZ(-180deg);">     At room temperature for no more than 6 hours from the time of dilution. This includes room temperature storage of the diluted solution, and the duration of infusion. Under refrigeration ...more  
Comment by enriquesuave on Sep 29, 2023 1:07pm
It seems unopened vial of Keytruda May be good for 2 years?
Comment by Rumpl3StiltSkin on Sep 29, 2023 3:44pm
Exactly, she is there for jv facilitation. Doesn't hurt that she is hot, IMO
Comment by Legit62 on Sep 30, 2023 7:47am
Dr. Lbiati utilizes her extensive clinical and business background to assist biopharmaceutical organizations to achieve their strategic objectives through: systematic achievement of their value inflection milestones, partnering of their promising drug candidates with large international pharmaceutical companies and ultimately increasing shareholder value., we are on the right path with the ight ...more  
Comment by Legit62 on Sep 30, 2023 7:48am
Shareholder value is what we are all waiting for
Comment by Legit62 on Sep 30, 2023 7:56am
Dr. Lbiati stated that, "I am very excited to finally get involved with the Canadian biotech ecosystem and I look forward to assisting Theralase® achieve its strategic objectives of commercialization through partnering of its lead pharmaceutical drug with large pharmaceutical organizations in North America and internationally. this is the reason she received her stock options and will ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250